Trial Profile

A Pilot Study of Chimeric Antigen Receptor (CAR) T Cells Targeting B7-H3 Antigen in Treating Patients With Recurrent and Refractory Glioblastoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti B7 H3 chimeric antigen receptor T-cell therapy BoYuan RunSheng Pharma (Primary) ; Anti B7 H3 chimeric antigen receptor T-cell therapy BoYuan RunSheng Pharma (Primary) ; Temozolomide
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

25 Dec 2022 Planned End Date changed from 1 Jul 2022 to 1 May 2024.
25 Dec 2022 Planned primary completion date changed from 1 May 2022 to 1 Mar 2024.
14 May 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com